Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
27 hedge funds and large institutions have $13.7M invested in Elevation Oncology in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
8% more funds holding
Funds holding: 25 → 27 (+2)
0.6% more ownership
Funds ownership: 61.31% → 61.91% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less capital invested
Capital invested by funds: $16.1M → $13.7M (-$2.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$487K |
| 2 |
AC
Annandale Capital
Dallas,
Texas
|
+$20.3K |
| 3 |
JP Morgan Chase
New York
|
+$4.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.81K |
| 5 |
BlackRock
New York
|
+$686 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$271K |
| 2 |
Renaissance Technologies
New York
|
-$90.1K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$44K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.22K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $86 | +$2 | +2 | +2% |
|
27
Bank of America
Charlotte,
North Carolina
| $16 | +$17 | +17 | New |
|
|
MAM
28
Marquette Asset Management
Minneapolis,
Minnesota
| – | -$44K | -38,951 | Closed |
|
|
29
Osaic Holdings
Scottsdale,
Arizona
| – | -$1K | -1,100 | Closed |
|
ELEV Hedge Fund Activity: Q4 2022 in Review
27 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2022, worth a combined $13.7M — down 15% from $16.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELEV positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $487K. The largest seller was TCG Crossover Management, cutting an estimated $271K.
- 27 institutional investors held Elevation Oncology (ELEV) as of Q4 2022, up from 25 in Q3 2022.
- Funds reported $13.7M of Elevation Oncology stock for Q4 2022, down 15% quarter-over-quarter.
- 5 funds opened new Elevation Oncology positions in Q4 2022 and 3 closed out, a net change of +2 holders.
- The largest Elevation Oncology buyer in Q4 2022 was Tang Capital Management, an estimated $487K added.
- The largest Elevation Oncology seller in Q4 2022 was TCG Crossover Management, an estimated $271K sold.
Based on aggregated 13F filings for Q4 2022.